Why Researchers Are Turning to the Nose as a Peptide Delivery Route
The route of administration may be one of the most underappreciated variables in peptide research. While subcutaneous injection has long been the standard, a growing body of preclinical and early-phase research is drawing serious scientific attention toward intranasal delivery as a compelling alternative — particularly for peptides intended to reach the central nervous system.
Intranasal peptide administration bypasses several major pharmacokinetic obstacles. The nasal mucosa offers a highly vascularized surface area, and the olfactory and trigeminal nerve pathways provide a direct anatomical corridor toward the brain — effectively sidestepping the blood-brain barrier (BBB) that blocks many systemically administered compounds.
The Science Behind Intranasal Peptide Delivery
The nasal cavity's architecture makes it uniquely suited for peptide uptake. The olfactory epithelium, located in the upper nasal passage, sits in close proximity to the olfactory bulb, which connects directly to the central nervous system. This pathway has been studied extensively as a non-invasive route for delivering neuroactive compounds that would otherwise show poor CNS penetration when administered orally or intravenously.
Key Mechanisms Identified in Research
- Transcellular transport: Peptide molecules may cross epithelial cells directly through the mucosal lining via endocytosis or passive diffusion.
- Paracellular transport: Small peptides may pass between epithelial cells through tight junctions, reaching the submucosal vasculature rapidly.
- Olfactory nerve pathway: Research suggests some peptide molecules may travel along olfactory nerve axons toward the olfactory bulb, enabling CNS-targeted delivery without systemic circulation.
- Trigeminal nerve pathway: Studies indicate the trigeminal nerve provides an additional direct route, covering a broader area of the nasal cavity and offering another corridor toward brainstem structures.
A 2020 review published in Advanced Drug Delivery Reviews highlighted that intranasal delivery may achieve meaningful CNS concentrations for certain peptide classes within 30 minutes of administration, a timeline that compares favorably with other non-injectable routes.
Peptides Actively Studied via Intranasal Routes
Several research-grade peptides have been the subject of intranasal delivery investigations. Understanding which compounds have been studied this way — and why — offers valuable context for researchers evaluating administration methodology.
Semax and Selank
Among the most well-documented intranasal peptides in research literature, Semax (ACTH 4-7 Pro-Gly-Pro) and Selank (a heptapeptide analog of tuftsin) were both developed with intranasal administration in mind. Russian preclinical studies and early human-subject research have explored their cognitive and anxiolytic profiles via nasal delivery, with researchers noting relatively rapid onset compared to oral routes. Both peptides are considered research-grade compounds and are studied for their potential neuromodulatory properties.
Oxytocin and Insulin
Perhaps the most extensively studied intranasal peptides, oxytocin and intranasal insulin have generated a substantial body of literature. A series of studies published between 2010 and 2022 investigated how intranasally administered insulin may reach hypothalamic and hippocampal regions — areas inaccessible to peripherally injected insulin due to tight BBB regulation. These studies have informed the broader understanding of what makes a peptide a viable candidate for nasal delivery.
BPC-157 Intranasal Research
BPC-157, a pentadecapeptide derived from gastric juice proteins, has been explored across multiple administration routes in animal model research. While subcutaneous and oral routes dominate the literature, emerging preclinical data suggests intranasal delivery may offer systemic exposure with potential for CNS interaction. Bpc 157
Bioavailability Considerations: What the Research Indicates
Intranasal bioavailability for peptides is not uniform — it is highly dependent on molecular weight, lipophilicity, charge, and formulation. Research suggests that smaller peptides (typically under 1,000 Daltons) show more favorable nasal absorption profiles, while larger molecules may require permeation enhancers or carrier systems such as nanoparticles or cyclodextrins to achieve meaningful uptake.
A 2021 study in the Journal of Controlled Release examined how formulation excipients — including chitosan and hyaluronic acid — may improve mucosal residence time and peptide permeation, suggesting that delivery vehicle design is as critical as the peptide itself when evaluating intranasal protocols.
Mucociliary Clearance: A Key Research Challenge
One of the primary challenges identified in intranasal delivery research is mucociliary clearance — the natural mechanism by which the nasal epithelium sweeps foreign material toward the throat for elimination. Studies indicate that peptides deposited in the lower nasal cavity face clearance half-lives as short as 15-20 minutes, underscoring the importance of targeting the upper olfactory region for CNS-directed applications and using formulations designed to extend mucosal contact time.
Research Protocols and Administration Variables
For researchers evaluating intranasal peptide administration, several variables appear consistently in the literature as significant factors influencing outcomes:
- Volume per nostril: Most research protocols utilize volumes between 25-100 microliters per nostril to avoid anterior drip and maximize mucosal contact.
- Positioning: Some protocols involve a head-tilted-back or lateral head positioning during administration to encourage deposition toward the olfactory region.
- Peptide concentration: Higher concentrations in smaller volumes are generally preferred in research settings to minimize dilution at the mucosal surface.
- Device type: Metered-dose nasal spray devices produce more consistent droplet particle sizes compared to simple dropper systems, which research suggests may improve reproducibility across study subjects.
Comparing Intranasal to Other Administration Routes
Research comparing intranasal to subcutaneous administration for the same peptides reveals meaningful trade-offs. Subcutaneous injection typically offers higher and more predictable systemic bioavailability, while intranasal administration may offer preferential CNS targeting with lower systemic exposure — a distinction that may be advantageous depending on the research objective.
Oral peptide administration continues to face significant enzymatic degradation challenges in the GI tract, making intranasal and subcutaneous routes the predominant focus of serious peptide delivery research. Studies indicate that for neuropeptides specifically, intranasal delivery may achieve CNS-to-plasma ratios that subcutaneous administration cannot replicate, representing a mechanistically distinct pharmacokinetic profile worth continued investigation.
What This Means for the Peptide Research Community
The expanding body of intranasal peptide delivery research signals a maturing field that is moving beyond single-route assumptions. As analytical techniques improve — including the use of radiolabeled peptides and advanced neuroimaging to track CNS distribution — researchers are gaining a clearer mechanistic picture of when and why intranasal administration may be the methodologically optimal choice for specific research applications.
Maxx Labs remains committed to supporting the research community with high-purity, research-grade peptides formulated for investigational use. Explore our full catalog of research compounds at maxxlaboratories.com. Products
Disclaimer: All products offered by Maxx Labs are intended for research and laboratory use only. They are not intended for human consumption, and are not intended to treat, prevent, mitigate, or assessed any condition or disease. All information presented in this article is for educational purposes only and is not a substitute for professional informational content. Always consult a qualified healthcare provider before making any decisions related to health or supplementation.